Search

Author/Creator Behrens, F

1. AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis. (15th June 2017)

Authors:
Elewski, BE; Rich, PA; Behrens, F; Guillet, G; Geng, Z; Servin, O Reyes
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
1319
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. FRI0217 Impact of rituximab in combination with leflunomide and rituximab retreatment with two different dosages on patient-reported outcomes: results from a multicenter randomized placebo controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-STUDY). (15th June 2017)

Authors:
Köhm, M; Rossmanith, T; Dauth, S; Alten, R; Aringer, M; Backhaus, M; Burmester, G; Feist, E; Kellner, H; Krüger, K; Müller-Ladner, U; Rubbert-Roth, A; Tony, H-P; Wassenberg, S; Burkhardt, H; Behrens, F
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
565
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial. (15th June 2017)

Authors:
Gladman, DD; Rigby, WFC; Azevedo, VF; Behrens, F; Blanco, R; Kaszuba, A; Kudlacz, E; Wang, C; Menon, S; Hendrikx, T; Kanik, KS
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗